Watch the interview with Dr. Jeff Evans below.
Medivir’s investigator on the positive results directly from EASL
This week, Medivir presented positive final results from the phase Ib/IIa study on the combination of Fostrox and Lenvima for the treatment of advanced liver cancer. The results, presented at the EASL Liver Cancer Summit, demonstrate promising efficacy and safety. We spoke with Dr. Jeff Evans, one of the study investigators, directly from EASL in Paris.
Notes
Alligator comments on Henlius' phase III study
AstraZeneca's baxdrostat meets all Phase III targets
NOSA receives positive results from in vivo study
Iconovo reports Q2
NextCell recognized in FUJIFILM's strategic vision
NEWSLETTER
NEWS
Enzymatica's CEO comments on his resignation
Rights issue strengthens AlzeCure's position
AI-designed proteins are created in seconds
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
